DAEWOONG Pharmaceutical Co. Ltd.’s technology, through its latest neurotoxin drug Nabota, is expecting to double its target share of the Philippine aesthetic market by next year on the back of a strong local sales force.
Nabota Philippines Brand Manager Christopher Cachuela told the BusinessMirror they are on track to meet their 2015 goal of 15 percent and surpass it to 30 percent in 2016 since they have already established their presence in the country.
“I’m very confident by this year we will be able to achieve, or maybe exceed that [of next year],” he said.
Since the launch of Nabota (Clostridium Botulinum Toxin Type A) last June in the domestic market, the executive said they have, so far, achieved their business goals and already dominated most areas nationwide. “In the first half, we only focused on Metro Manila. But this second half, we will expand to North and South Luzon and then, hopefully, by the first quarter of next year, we will penetrate the Visayas and Mindanao,” Cachuela noted.
He also bared their plans of expanding their sales field force to reach all major cities by the end of this year.
“Actually, from three product specialists, we already added one more product specialist, plus we also hired one marketing associate and one district supervisor,” he cited.
Developed through Daewoong Pharmaceutical Co. Ltd.’s technology at its facility in South Korea, Nabota is an antiwrinkle product that boasts of high purity at 98.7 percent on the back of the growing local aesthetic market.
Proven to be safe and effective, with stability and antidiffusion properties, it is now gaining popularity in the country through the company’s local doctor-clients, such as dermatologists, plastic surgeons, cosmetics surgeons and aesthetic surgeons. Industry figures show that the local market for aesthetic products grows in a year by 11 percent, and this is projected to increase further given the country’s continued flourishing economy and strong purchasing power of consumers.
It is for this reason that the Philippines is now chosen as the model market for Nabota Expert’s Journal—a workbook aimed at educating doctors on facial anatomy, as well as enhancing their skills on proper documentation and positions of filler and toxin, according to the brand manager.
This recently launched module also includes precautionary measures during complications on how to do it. “We took a long time [doing the workbook] because it had to be with the collaboration with the local speakers, the advisory board, our country manager and, of course, we also took the insights of the Korean clinicians,” said Dr. Maria Cristina Puyat, who is the chief clinical adviser and Nabota pioneer in the Philippines.
“So we’re supposed to have a cascade of it in the next two to three months, and then, whatever the suggestions of our colleagues, we will put them together and have a second addition. Hopefully, it won’t stop there. After that, it will continue. I’m sure that Daewong Pharma will support our doctors through this workbook,” she added.
While Nabota Expert’s Journal is just for Philippine implementation at present, this pioneering module will soon roll out in other markets of Nabota. Cachuela said it will be used also in Thailand and Latin America next year, as well as their headquarters in Korea. This journal is complementary to Nabota’s world-class standards as it is developed from biotechnology of more than three decades of know-how and manufactured from Daewoong’s good manufacturing practice.
1 comment
More power!